Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

vTv Therapeutics to Participate in Upcoming Investor Conferences

globenewswire.com
VTVT The article announces vTv Therapeutics' participation in upcoming investor conferences, which is a standard corporate event. It highlights their lead drug candidate, cadisegliatin, and its potential, but also includes standard disclaimers about ongoing investigations and lack of guaranteed approval or commercial availability. The overall tone is informative rather than strongly positive or negative.

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Time: 11:20 AM ET

Format: Presentation Only

Location: Virtual

Webcast Link

TD Cowen 46th Annual Health Care Conference

Date: Tuesday, March 3, 2026

Time: 9:50 AM ET

Format: Presentation and 1x1 Meetings

Location: Boston, MA

Webcast Link

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact

John Fraunces

LifeSci Advisors, LLC

jfraunces@lifesciadvisors.com

Media Contact

Caren Begun

TellMed Strategies

201-396-8551

caren.begun@tmstrat.com